The US Supreme Court has agreed to review Matrixx Initiatives Inc v Siracusano, a case that has the potential to determine which adverse event reports drug and medical device companies must disclose to shareholders to avoid securities suits1.
Specifically, the case addresses the question of whether Matrixx, a company marketing the homeopathic intranasal cold therapy Zicam (zinc gluconate), had a duty to publicly disclose adverse drug event reports to shareholders even though the events were not statistically significant...
Please Login to read the full article.
